{"ticker": {"uuid": "482046b4-fa61-4eeb-83cd-8623c15479d1", "symbol": "NVSN", "name": "Novartis AG", "exchange": "MEX", "country": "MX", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Novartis AG stock (CH0012005267): Vanrafia Phase III data highlight kidney drug progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNLVVKaFZVbnhOWkQ4S3BYek9kY3BlbWpHWEdqWjlVelRid2hzTzBwVml2ZVJSdVNPak9BbGozV1B1clJnamtqeGRndW5PTmFFNHBjNF9OSVp4ZU9Bc3M1RTdkZkd4YWdDbGtaWUdqRzhZSjU2aV9tZmhNZGhwQ2lQMGZ2VDhMQklRU04zSFNzUWVud2FBTktSWWJpYV80LXBxbUhwTjNRZERVUUlMdkVTMzVZVi1YNnI3NUx1TnJnT2F5U0tyNE84S1VB?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG Tokenized Stock (NVS) Historical Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTFBZc1pMemRlLWd1LWV2YXRVQV81bm1TcU8tYUxVOVp1cF9YaURPUXNpV2tEc2VQdkM1dzN3T0FkU1ByRUZVX0dCbU1OdU5GdDI1ZDZjcDRSaHRRWElqRUNmemdMWkFIWEs3bEJfZVhfWlA0bUkzdFNzclBmZzNCZw?oc=5", "source_name": "CoinCodex", "published_at": "2026-05-21T15:08:24+00:00", "published_display": "21 May 2026 15:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOSlkyOHlDbVBqSzhWX3dXMXFLVmdYdnhBYmFpOUdGRWhHZkgtb1VUd1g4TW9jenhpVDM1UVhVRzg5XzZaeWNsRy1OeHBUcEw3NDVucWlFdkREX3dnU3JpY19WZHBOck5JZ3N5aDgtLUw5QU85Z19QRG51Ry0tS056SVhacVpPejB0UkxUSFNiOE5pd3h2M2NGcGI1Smg4bnh5SzVHaHV2dkxJN2J3aGMxdGFiX2RSTkYyVUtOc0NabkoxclQ3cGc?oc=5", "source_name": "PR Newswire", "published_at": "2025-10-26T07:00:00+00:00", "published_display": "26 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQYnZsSldkcTFNeEJ0YWtPZUlONFpvalBVZzNkMThSWUtMemRlMEswOWNVQ1hFLXN3dlQzOU1DaVNSS21BbEhMNVNHZnFUNl90N0dPLWlMRC1MbjY5VW9XNHh3QlhkajBMamtKMEhmMzRZNDJhTTg2aXNHTmZiWk4yVXZ4aVYzdFc1dGRWNDRpUFA0ejhWbmRha0I3eFhYYWt5bGtCTU9vWmxBV3h0cE0tX3dYQmoyYTZOdDVZRUlkMUViMVdVVGF2SGVJd25zOXE0d0huUnRRaTRsSHpRY1VwQU50RmZ0T0U?oc=5", "source_name": "Reuters", "published_at": "2025-10-26T07:00:00+00:00", "published_display": "26 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQTEw1emYtTS1rb18wRGpyeHpsTDcwNnY0ZFE2dzRCcTdxYVN0NTl0VjRldlpMU1hCOVdZZ0MzcFAyRzlFanRNaDNHUEFHTnlkUG4zWnNObFRkQVd4TkZFaVpLZGJDMmJOTVFpWllfZUJMYTN1SXN0N09IcWZRM2RGRHc5WmE0c2NKcUVWNkUyQVJaeWxfSUNsWHQtRkJLMjFIMXdYbEtFQVBKTU9rZWs3NktlVHpHRmRyQ2ZCYW5tSHZoUmNYS3Fj?oc=5", "source_name": "PR Newswire", "published_at": "2025-04-30T07:00:00+00:00", "published_display": "30 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis ups yearly outlook but market focuses on disappointing Pluvicto", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQVXJaN2M2aGM2VHhxaWFXOVBuZ2Vhc2sxendPOTVNYmlxZE9lZkFhZE43UTFLTnptdUl3MTFtT3hsRGhaZzFTT1plc0NsbUtQVVo1WlU5d0x6MGhERXZGTllNekU0aEtOQ3M0Qlg2dDUwekN2SXMwQ3dXc1hKUjB6RnVuWjJKenlHRk1OMzBXX2MwcjhyeUROSnV6anpPRTVINnlCQkNiWG40d1JBa0xjRVoySHBKOHhsTE9uUWExMWNwd3lua3d5dg?oc=5", "source_name": "Reuters", "published_at": "2024-10-29T07:00:00+00:00", "published_display": "29 Oct 2024 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cash-flush Novartis launches new share buyback of up to $15 bln", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNaFpJdDRKTFdpUDNRd25OeVpfNmFQaVhybm1LNGFpb1NrUVdFRWFaQU1yb3FORlMwbmx3RmxMNVNyNmYwWEJBbUZmeFBjWUFsU2p2QTJ0N1FjS3JUcFBKTkRBWVBJZENHTDR1TE8xajAtZzdzMDNNSDlJYnhjeEZFdGNKWkZKWUJzOFdtek9zT0dkU1JxRnFVQ19hbmRCdng1TU5tam53QkhDdV9YMnZyUkpwM3lPWGZu?oc=5", "source_name": "Reuters", "published_at": "2021-12-15T08:00:00+00:00", "published_display": "15 Dec 2021 08:00", "sentiment": "positive", "sentiment_pct": 62, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roche controlling family won't have to make offer after Novartis deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxObjdiWUVhV0ZJekVTWnNJY0xlN0lGZGRDSUt2RjdtTVhLQ3llaWoxY3pIOFI0TDdlQVNxNFNEVmV2Q012Z3UzOWFOUjl1NHZScnlwN0w4eG9ZUlNhQWVNSVpnaUdYRUtaaEF5NS1qemxIbUFCeFhpWVZqVEpteW90NzVRUXpRb1RGTWJXcmxScmNOWkpOdHN3QlktMnF0aEZfN1ZfTEpob3drS3lJSXA5V0lvTHl2RnFJRG16WFRGLTZjVWhYNXdGM21hbnRSdXdZcVJsVENvdzc?oc=5", "source_name": "Reuters", "published_at": "2021-11-05T07:00:00+00:00", "published_display": "05 Nov 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG (NVS) Stock Price, Trades & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE16cGZ0Zzd5X0U1eFp4U1NYRUZMQUhwSTdWN1hJc0tTc29XZWFwZ1JIZlR2MnR4NU43dkN3UUMtMnZ1V3Y0TDY4M081aWF5UDRpWmdYX1d3?oc=5", "source_name": "GuruFocus", "published_at": "2019-04-15T21:08:05+00:00", "published_display": "15 Apr 2019 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG Consolidates Its IT Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTFA1MVhKdl91WVZnU3dMUnZzNXIzSmsyQnA2eFNzX29GWGJlcDhIYl9pS1JicUg1enhReGhycl9xY3hacE9sNjZXZjY2Sy1qLUVwZXp3R3BScnVwLVE0VUVjYnd4c0FWRF84dzEwUA?oc=5", "source_name": "BioSpace", "published_at": "2015-02-20T08:00:00+00:00", "published_display": "20 Feb 2015 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Novartis AG stock (CH0012005267): Vanrafia Phase III data highlight kidney drug progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNLVVKaFZVbnhOWkQ4S3BYek9kY3BlbWpHWEdqWjlVelRid2hzTzBwVml2ZVJSdVNPak9BbGozV1B1clJnamtqeGRndW5PTmFFNHBjNF9OSVp4ZU9Bc3M1RTdkZkd4YWdDbGtaWUdqRzhZSjU2aV9tZmhNZGhwQ2lQMGZ2VDhMQklRU04zSFNzUWVud2FBTktSWWJpYV80LXBxbUhwTjNRZERVUUlMdkVTMzVZVi1YNnI3NUx1TnJnT2F5U0tyNE84S1VB?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG Tokenized Stock (NVS) Historical Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTFBZc1pMemRlLWd1LWV2YXRVQV81bm1TcU8tYUxVOVp1cF9YaURPUXNpV2tEc2VQdkM1dzN3T0FkU1ByRUZVX0dCbU1OdU5GdDI1ZDZjcDRSaHRRWElqRUNmemdMWkFIWEs3bEJfZVhfWlA0bUkzdFNzclBmZzNCZw?oc=5", "source_name": "CoinCodex", "published_at": "2026-05-21T15:08:24+00:00", "published_display": "21 May 2026 15:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOSlkyOHlDbVBqSzhWX3dXMXFLVmdYdnhBYmFpOUdGRWhHZkgtb1VUd1g4TW9jenhpVDM1UVhVRzg5XzZaeWNsRy1OeHBUcEw3NDVucWlFdkREX3dnU3JpY19WZHBOck5JZ3N5aDgtLUw5QU85Z19QRG51Ry0tS056SVhacVpPejB0UkxUSFNiOE5pd3h2M2NGcGI1Smg4bnh5SzVHaHV2dkxJN2J3aGMxdGFiX2RSTkYyVUtOc0NabkoxclQ3cGc?oc=5", "source_name": "PR Newswire", "published_at": "2025-10-26T07:00:00+00:00", "published_display": "26 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQYnZsSldkcTFNeEJ0YWtPZUlONFpvalBVZzNkMThSWUtMemRlMEswOWNVQ1hFLXN3dlQzOU1DaVNSS21BbEhMNVNHZnFUNl90N0dPLWlMRC1MbjY5VW9XNHh3QlhkajBMamtKMEhmMzRZNDJhTTg2aXNHTmZiWk4yVXZ4aVYzdFc1dGRWNDRpUFA0ejhWbmRha0I3eFhYYWt5bGtCTU9vWmxBV3h0cE0tX3dYQmoyYTZOdDVZRUlkMUViMVdVVGF2SGVJd25zOXE0d0huUnRRaTRsSHpRY1VwQU50RmZ0T0U?oc=5", "source_name": "Reuters", "published_at": "2025-10-26T07:00:00+00:00", "published_display": "26 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQTEw1emYtTS1rb18wRGpyeHpsTDcwNnY0ZFE2dzRCcTdxYVN0NTl0VjRldlpMU1hCOVdZZ0MzcFAyRzlFanRNaDNHUEFHTnlkUG4zWnNObFRkQVd4TkZFaVpLZGJDMmJOTVFpWllfZUJMYTN1SXN0N09IcWZRM2RGRHc5WmE0c2NKcUVWNkUyQVJaeWxfSUNsWHQtRkJLMjFIMXdYbEtFQVBKTU9rZWs3NktlVHpHRmRyQ2ZCYW5tSHZoUmNYS3Fj?oc=5", "source_name": "PR Newswire", "published_at": "2025-04-30T07:00:00+00:00", "published_display": "30 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis ups yearly outlook but market focuses on disappointing Pluvicto", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQVXJaN2M2aGM2VHhxaWFXOVBuZ2Vhc2sxendPOTVNYmlxZE9lZkFhZE43UTFLTnptdUl3MTFtT3hsRGhaZzFTT1plc0NsbUtQVVo1WlU5d0x6MGhERXZGTllNekU0aEtOQ3M0Qlg2dDUwekN2SXMwQ3dXc1hKUjB6RnVuWjJKenlHRk1OMzBXX2MwcjhyeUROSnV6anpPRTVINnlCQkNiWG40d1JBa0xjRVoySHBKOHhsTE9uUWExMWNwd3lua3d5dg?oc=5", "source_name": "Reuters", "published_at": "2024-10-29T07:00:00+00:00", "published_display": "29 Oct 2024 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cash-flush Novartis launches new share buyback of up to $15 bln", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNaFpJdDRKTFdpUDNRd25OeVpfNmFQaVhybm1LNGFpb1NrUVdFRWFaQU1yb3FORlMwbmx3RmxMNVNyNmYwWEJBbUZmeFBjWUFsU2p2QTJ0N1FjS3JUcFBKTkRBWVBJZENHTDR1TE8xajAtZzdzMDNNSDlJYnhjeEZFdGNKWkZKWUJzOFdtek9zT0dkU1JxRnFVQ19hbmRCdng1TU5tam53QkhDdV9YMnZyUkpwM3lPWGZu?oc=5", "source_name": "Reuters", "published_at": "2021-12-15T08:00:00+00:00", "published_display": "15 Dec 2021 08:00", "sentiment": "positive", "sentiment_pct": 62, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roche controlling family won't have to make offer after Novartis deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxObjdiWUVhV0ZJekVTWnNJY0xlN0lGZGRDSUt2RjdtTVhLQ3llaWoxY3pIOFI0TDdlQVNxNFNEVmV2Q012Z3UzOWFOUjl1NHZScnlwN0w4eG9ZUlNhQWVNSVpnaUdYRUtaaEF5NS1qemxIbUFCeFhpWVZqVEpteW90NzVRUXpRb1RGTWJXcmxScmNOWkpOdHN3QlktMnF0aEZfN1ZfTEpob3drS3lJSXA5V0lvTHl2RnFJRG16WFRGLTZjVWhYNXdGM21hbnRSdXdZcVJsVENvdzc?oc=5", "source_name": "Reuters", "published_at": "2021-11-05T07:00:00+00:00", "published_display": "05 Nov 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG (NVS) Stock Price, Trades & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE16cGZ0Zzd5X0U1eFp4U1NYRUZMQUhwSTdWN1hJc0tTc29XZWFwZ1JIZlR2MnR4NU43dkN3UUMtMnZ1V3Y0TDY4M081aWF5UDRpWmdYX1d3?oc=5", "source_name": "GuruFocus", "published_at": "2019-04-15T21:08:05+00:00", "published_display": "15 Apr 2019 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis AG Consolidates Its IT Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTFA1MVhKdl91WVZnU3dMUnZzNXIzSmsyQnA2eFNzX29GWGJlcDhIYl9pS1JicUg1enhReGhycl9xY3hacE9sNjZXZjY2Sy1qLUVwZXp3R3BScnVwLVE0VUVjYnd4c0FWRF84dzEwUA?oc=5", "source_name": "BioSpace", "published_at": "2015-02-20T08:00:00+00:00", "published_display": "20 Feb 2015 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 66, "total_relevant": 10, "sentiment_summary": {"positive": 1, "negative": 1, "neutral": 8, "score": 49, "total": 10, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 3.3, "count": 6}, {"event": "deals", "label": "Deals and strategy", "weight": 1.8, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.9, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.9, "count": 1}], "positive_events": 1, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 2563.0, "latest_week": "2026-06-19", "one_week_move": -1.5, "four_week_move": -2.8, "twelve_week_move": -9.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.971355, "market_dynamics_buy_signal": false, "relative_strength": -0.404268, "fair_value_gap": 23.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 26.441, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.5% over one week, -2.8% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 58, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Reuters", "count": 4}, {"label": "PR Newswire", "count": 2}, {"label": "AD HOC NEWS", "count": 1}, {"label": "CoinCodex", "count": 1}, {"label": "GuruFocus", "count": 1}, {"label": "BioSpace", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 10}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 6}, {"label": "Deals and strategy", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "49/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "10", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.5% over one week, -2.8% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Novartis AG stock (CH0012005267): Vanrafia Phase III data highlight kidney drug progress"}], "updated_at": "2026-06-22T12:33:14.626816+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}